Development of new drug deliverty system with liposome consist of comparable to the lipid composition of oral cancer cancer cell membrane
开发新的脂质体药物递送系统,其组成与口腔癌癌细胞膜的脂质成分相当
基本信息
- 批准号:08672311
- 负责人:
- 金额:$ 1.47万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:1996
- 资助国家:日本
- 起止时间:1996 至 1997
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
It has long been known that the effect of anti-cancer drug is dependent on the histological type of the target cancer cells. We have examined the sensitivity to cisplatin, doxorubicin and peplomycin of five human cancer cell lines by growth assay in serum-free culture. Of the cell line tested, slivary gland adenocarcinoma cell lines (SAC) were shown to be generally more sensitive to cisplatin than squmous cell carcinoma cell lines (SCC) in vitro, and SCC were relatively resistant to cisplatin. On the other hand, SCC were more sensitive to doxorubicin and peplomycin in comparison to SAC.It is known that cisplatin, peplomycin and doxorubicin were uptake in the cells by passive transport system. We have speculated that heterogeneity of these anticancer drug effects is correlated with intracellular drug level, resulted from the difference of membrane permiability of cancer cells. We studied the membrane lipid composition of the cell lines in serum-free medium, which determine the membrane … More permiability. We have found that 70% of total membrane lipid in SCC is phosholipid and remainder is free cholesterol. On the other hand, 80% of total membrane lipid in SAC in neutral lipid such as triglyceride and esterified cholesterol, and 20% is phospholipid. The higher neutral lipid level of SAC which should have resulted in decreased membrane fluidity, is consistent with the higher accumulation of cisplatin compared to SCC.On the other hand, doxorubicin and peplomycin exhibited high cytotoxicity to SCC,which membrane lipid consisted of phospholipid mainly and the membrane fluidity was higher than that of SAC.These result suggest that the lipid composition of cancer cell membranes is major factor determining the sensitivity of cancer cells to cisplatin, peplomycin and doxorubicin. Thus, we have designed liposome which is comparable to the lipid composition of SCC cell membrane, constructed the liposome-entrapped cisplatin and examined sensitivity to the liposome-entrapped cisplatin of both SCC and SAC by growth assay in serum-free culture. As the reult, the liposome-entrapped cisplatin exhibited enhanced cytotoxicity on SCC compare to either cisplatin alone or cisplatin-liposome mixture. And we have shown that epidermal growth factor receptor (EGFR) was over-expression on SCC and SAC.Then we made monoclonal antibody (12-93) to EGFR and combined liposome-entrapped cisplatin with anti-EGFR monoclonal antibody with avidin-biotin method. We have examined sensitivity to the liposome united with anti-EGFR monoclonal antibody of both SCC and SAC in vitro. This liposome had a tendency to enhance cytotoxicity on SCC and SAC compare to liposome-entrapped cisplatin. Less
人们早就知道抗癌药物的效果取决于靶癌细胞的组织学类型。我们用无血清培养法测定了五种人癌细胞系对顺铂、阿霉素和培洛霉素的敏感性。在所测试的细胞系中,在体外,唾液腺腺癌细胞系(SAC)通常比鳞状细胞癌细胞系(SCC)对顺铂更敏感,而SCC对顺铂相对耐药。另一方面,SCC比SAC对阿霉素和培洛霉素更敏感,已知顺铂、培洛霉素和阿霉素在细胞中通过被动转运系统摄取。我们推测,这些抗癌药物效应的异质性与细胞内药物水平有关,这是由于癌细胞膜通透性的差异造成的。我们研究了无血清培养基中细胞系的膜脂组成,这决定了膜 ...更多信息 可渗透性我们发现SCC中磷脂占总膜脂的70%,其余为游离胆固醇。另一方面,SAC中80%的总膜脂为中性脂质,如甘油三酯和酯化胆固醇,20%为磷脂。SAC较高的中性脂质水平应导致膜流动性降低,这与顺铂的蓄积高于SCC相一致。另一方面,阿霉素和培洛霉素对SCC表现出较高的细胞毒性,细胞膜脂主要由磷脂组成,膜流动性高于SAC,提示癌细胞膜的脂质组成是决定癌细胞增殖的主要因素。癌细胞对顺铂、培洛霉素和阿霉素的敏感性。因此,我们设计了脂质体,这是可比的脂质体组成的SCC细胞膜,构建了脂质体包埋顺铂和检查敏感性的脂质体包埋顺铂的SCC和SAC的生长测定在无血清培养。结果表明,脂质体包埋顺铂对SCC的细胞毒作用比顺铂单独或顺铂-脂质体混合物更强。本研究制备了表皮生长因子受体(EGFR)单克隆抗体(12-93),并采用亲和素-生物素法将脂质体包裹的顺铂(DDP)与抗EGFR单克隆抗体(12-93)偶联。我们在体外检测了SCC和SAC对脂质体联合抗EGFR单克隆抗体的敏感性。与脂质体包裹的顺铂相比,该脂质体具有增强对SCC和SAC的细胞毒性的趋势。少
项目成果
期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
虎谷 茂昭: "口腔癌細胞の膜脂質組成の相違に基づく抗癌剤感受性" Tiss. Cult. Res. Commun.15. 147-153 (1996)
Shigeaki Toratani:“基于口腔癌细胞膜脂质成分差异的抗癌药物敏感性”Res. Commun.147-153 (1996)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
虎谷 茂昭: "癌細胞膜の脂質組成の差を利用した癌化学療法の基礎的研究" 日本癌治療学会誌. 31・7. 413-419 (1996)
Shigeaki Toratani:“利用癌细胞膜脂质组成的差异进行癌症化疗的基础研究”日本癌症治疗学会杂志31・7(1996)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
S.Toratani, T.Okamoto, T.Shinki, T.Osaki, M.Yabumoto, R.Tanaka, R.Tani and K.Takada: "Sensitivities of Oral Cancer Cells to Various anti-Cancer Drugs based on the Difference of the Membrane Lipid Composition." Tiss.Cult.Res.Commun.15. 147-153 (1996)
S.Toratani、T.Okamoto、T.Shinki、T.Osaki、M.Yabumoto、R.Tanaka、R.Tani 和 K.Takada:“基于口腔癌细胞对各种抗癌药物的敏感性的差异
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
虎谷茂昭: "口腔癌細胞の膜脂質組成の相違に基づく抗癌剤感受性" Tiss. Cult. Res. Commun.15. 147-153 (1996)
Shigeaki Toratani:“基于口腔癌细胞膜脂质成分差异的抗癌药物敏感性”Res. Commun.147-153 (1996)。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
S.Toratani, T.Okamoto, T.Osaki, T.Shinki and K.Takada: "A Study of Cancer Chemotherapy Based on the Difference in Lipid Composition of Cancer Cell Membrane." J.Jpn.Soc.Cancer Ther.31. 413-419 (1996)
S.Toratani、T.Okamoto、T.Osaki、T.Shinki 和 K.Takada:“基于癌细胞膜脂质成分差异的癌症化疗研究”。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TORATANI Shigeaki其他文献
TORATANI Shigeaki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TORATANI Shigeaki', 18)}}的其他基金
Proteomic analysis of molecular-targeted therapy against KGFR of salivary gland carcinomas
唾液腺癌 KGFR 分子靶向治疗的蛋白质组学分析
- 批准号:
18592184 - 财政年份:2006
- 资助金额:
$ 1.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of targeting therapy using specific difference of lipid composition of oral cancer cell, resistant
利用口腔癌细胞脂质成分的特异性差异开发靶向治疗,耐药
- 批准号:
13672098 - 财政年份:2001
- 资助金额:
$ 1.47万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of photodynamic therapy to early stage oral cancer using drug delivery system
使用药物输送系统开发早期口腔癌光动力疗法
- 批准号:
11470438 - 财政年份:1999
- 资助金额:
$ 1.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B).
New targeting therapy with complex of liposome, consist of comparable lipid composition of oral cancer cells, and anti-EGF receptor antibody.
采用脂质体复合物的新型靶向治疗,由口腔癌细胞的相似脂质成分和抗 EGF 受体抗体组成。
- 批准号:
10557191 - 财政年份:1998
- 资助金额:
$ 1.47万 - 项目类别:
Grant-in-Aid for Scientific Research (B)














{{item.name}}会员




